Advanced search×

Live case demonstrations: patient safety, ethics, consent, and conflicts.

David F DF Kallmes, Harry J HJ Cloft, Andrew A Molyneux, Ingrid I Burger, Waleed W Brinjikji, and Kieren P KP Murphy

Lancet 377(9776):1539-41 (2011) PMID 21531268

Copyright © 2011 Elsevier Ltd. All rights reserved.

DOI: 10.1016/S0140-6736(11)60357-7
Version: za2963e q8zae q8zb4 q8zcf q8zd6 q8ze9 q8zf1 q8zga

Similar articles you may find interesting…

  1. An Intelligent System to Detect, Avoid and Maintain Potholes: A Graph Theoretic Approach
    Shreyas Balakuntala, Sandeep Venkatesh, and Sunil Kumar KM

    arXiv:1305.5522 [cs.AI] 23 May 2013

    We propose a novel conceptual framework where a Centralized system, classifies the road based upon the level of damage. The Centralized system also identifies the traffic intensity thereby prioritizing The roads that need quick action to be taken upon. Moreover, the system helps The driver to detect...
    View PDF
  2. Factors associated with reduced efficacy of sitagliptin therapy: analysis of 93 patients with type 2 diabetes treated for 1.5 years or longe...
    Akira Kanamori and Ikuro Matsuba

    J Clin Med Res 5(3):217-21 (2013) PMID 23671547

    Several studies have shown the effectiveness of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for type 2 diabetes, with a hypoglycemic effect being demonstrated both when it is administered alone or in combination with other oral antidiabetic agents. However, there are few reports...
    PDF not found
  3. Randomized, open-label study to evaluate patient-reported outcomes with fingolimod after changing from prior disease-modifying therapy for r...
    Mark Cascione, Daniel Wynn, and Kevin McCague

    J Med Econ (2013) PMID 23647445

    Results of the EPOC study are anticipated in early 2013 and will inform treatment selection by providing patient-centered data on therapy switch to fingolimod or standard-of-care DMTs. Trial Registration: ClinicalTrials.gov NCT01216072....